JNJ

JOHNSON & JOHNSON

JOHNSON & JOHNSON (JNJ) has 11 SEC Form 4 filings (101 transaction rows) in the rolling window, disclosed by 5 distinct insiders. Most recent filing: May 4, 2026.

Insiders have net sold $57.0M over the trailing 6 months.

  • Industry:Drug Manufacturers - General
  • CEO:Joaquin Duato
  • Employees:141,700
  • HQ:New Brunswick, NJ, US
  • IPO:1962-01-02

Insider Buying

$0

reported purchases (SEC code P)

Insider Selling

$57.0M

reported sales (SEC code S)

Unique Insiders

5

in the rolling window

Market Cap

$601.7B

latest known value

Earnings: last 7 quarters

EstimatedActual
Source
Wolk Joseph JFirst filing
Sale$21.8MFeb 18SEC ↗
Swanson James D.First filing
Sale$10.1MFeb 18SEC ↗
Swanson James D.First filing
Sale$5.0MFeb 18SEC ↗
REED JOHN CFirst filing
Sale$13.1MFeb 18SEC ↗
Schmid TimothyFirst filing
Sale$5.5MFeb 18SEC ↗
Broadhurst VanessaFirst filing
Sale$1.5MFeb 18SEC ↗

Congress trading JNJ

See timeline →
  • RRep. Thomas H. KeanSale$1,001 - $15,0002026-06-02
  • RRep. Thomas H. KeanSale$1,001 - $15,0002026-06-29
  • DRep. Lloyd DoggettPurchase$1,001 - $15,0002026-06-09
  • DRep. Ro KhannaSale$1,001 - $15,0002026-05-01
  • DRep. Ro KhannaPurchase$15,001 - $50,0002026-04-13

STOCK Act disclosures are filed up to 45 days after the trade. Amount is a disclosed range, not an exact figure.

Related companies

JOHNSON & JOHNSON is in the Healthcare sector.